Corbus Pharmaceuticals(DE:3371)
€2.75-0.55 (-16.55%)
DE:3371
Corbus Pharmaceuticals ownership
€2.75
At close:-0.55 (-16.55%)
Corbus Pharmaceuticals (3371) Ownership - Who Owns Corbus Pharmaceuticals?
0 Followers
Corbus Pharmaceuticals (3371) Ownership Overview
- 12.09% Insiders
- 6.92% Mutual Funds
- 63.38% Other Institutional Investors
- 9.00% ETFs
- 8.61% Public Companies and Individual Investors
The ownership structure of Corbus Pharmaceuticals (DE:3371) stock is a mix of institutional, retail, and individual investors. Approximately 79.30% of the company’s stock is owned by Institutional Investors, 12.09% is owned by Insiders, and 8.61% is owned by Public Companies and Individual Investors.
The ownership structure of Corbus Pharmaceuticals (DE:3371) stock is a mix of institutional, retail, and individual investors. Approximately 79.30% of the company’s stock is owned by Institutional Investors, 12.09% is owned by Insiders, and 8.61% is owned by Public Companies and Individual Investors.
Recent Insider Trading Activity
| Date | Name | Activity | Value |
|---|---|---|---|
| Nov 01, 2026 | Cormorant Asset Management, Llc | $1,742,500 | |
| Aug 11, 2026 | Nishant C Saxena | $25,012 | |
| Jun 02, 2026 | Nishant C Saxena | $101,205 | |
| Mar 03, 2026 | Dominic Smethurst | $50,544 |
Recent Hedge Fund Trading Activity
| Date | Firm | Activity | Value |
|---|
Top Shareholders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| Cormorant Asset Management, Llc | 1,919,971 | Insider | 9.32% | 5,800,232 |
| Peter Kolchinsky | 1,914,788 | Institution | 9.29% | 5,784,575 |
| BlackRock, Inc. | 1,749,919 | Institution | 8.49% | 5,286,505 |
| Vanguard Index Funds | 741,885 | Institution | 3.60% | 2,241,235 |
| Vanguard | 735,900 | Institution | 3.57% | 2,223,154 |
| Ishares | 638,868 | Institution | 3.10% | 1,930,020 |
| Fidelity Salem Street Trust | 205,319 | Institution | 1.00% | 620,269 |
| Yuval Cohen | 157,316 | Insider | 0.76% | 475,252 |
| Global X | 151,958 | Institution | 0.74% | 459,065 |
| Fidelity Concord Street Trust | 128,430 | Institution | 0.62% | 387,987 |
Top Mutual Fund Holders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| Vanguard Index Funds | 741,885 | Institution | 3.60% | 2,241,235 |
| Fidelity Salem Street Trust | 205,319 | Institution | 1.00% | 620,269 |
| Fidelity Concord Street Trust | 128,430 | Institution | 0.62% | 387,987 |
| Vanguard Scottsdale Funds | 111,529 | Institution | 0.54% | 336,929 |
| Dfa Investment Dimensions Group Inc | 73,194 | Institution | 0.36% | 221,119 |
| Schwab Capital Trust | 59,702 | Institution | 0.29% | 180,360 |
| Tiaa-cref Funds | 22,308 | Institution | 0.11% | 67,392 |
| Goldman Sachs Trust | 21,356 | Institution | 0.10% | 64,516 |
| T. Rowe Price Index Trust, Inc. | 15,083 | Institution | 0.07% | 45,566 |
| Vanguard Institutional Index Funds | 11,420 | Institution | 0.06% | 34,500 |
FAQ
Who Owns Corbus Pharmaceuticals (DE:3371)?
According to the latest TipRanks data, approximately 79.30% of the company's stock is held by institutional investors, 12.09% is held by insiders, and 8.61% is held by public companies and individual investors.
What percentage of Corbus Pharmaceuticals (DE:3371) stock is held by institutional investors?
According to the latest TipRanks data, approximately 79.30% of Corbus Pharmaceuticals (DE:3371) stock is held by institutional investors: 6.92% by mutual funds, 9.00% by ETFs and 63.38% by other institutional investors.
What percentage of Corbus Pharmaceuticals (DE:3371) stock is held by retail investors?
According to the latest TipRanks data, approximately 8.61% of Corbus Pharmaceuticals (DE:3371) stock is held by public companies and individual investors.
Who owns the most shares of Corbus Pharmaceuticals (DE:3371)?
Cormorant Asset Management, LLC owns the most shares of Corbus Pharmaceuticals (DE:3371).
What is the significance of the ownership structure for a publicly traded company?
The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.

